Coverage
-
May 19, 2026
Novo Nordisk AS urged a New Jersey federal court to toss a proposed securities class action accusing it of misleading investors about its 2025 revenue outlook, arguing that the plaintiffs failed to plead any materially false or misleading statements.
3 other articles on this case.
View all »